Important step on the path to reconfiguring the STADA Supervisory Board
- Press Release
- Structured process for selection of candidates successfully completed
- Supervisory Board to propose to the Annual General Meeting on August 26, 2016 four candidates for election with a term of office of five years
- Chairman of the Supervisory Board Dr. Martin Abend: “Candidates have excellent expertise to help ensure first-class governance at STADA and to represent and support the interests of the Company and its shareholders.”
Bad Vilbel, July 6, 2016 –
The Supervisory Board of STADA Arzneimittel AG today announced the candidates for the Supervisory Board, who will be proposed for election with a term of office of five years to the Annual General Meeting on August 26, 2016. The candidates, whom the Nomination Committee of the Supervisory Board selected in a structured process based on a clear set of criteria and with the support of the renowned personnel consulting company Egon Zehnder, are to succeed Dr. Eckhard Brüggemann, Dr. K. F. Arnold Hertzsch, Dieter Koch and Constantin Meyer, who will resign from their positions at the end of the 2016 Annual General Meeting. Four of the six shareholder representatives on the Supervisory Board will be thus newly elected.
The candidates that will be proposed for election at the Annual General Meeting are:
- Rolf Hoffmann (57), previously Member of the Extended Executive Board of Amgen, Senior Vice President US Commercial Operations at Amgen
Mr. Hoffmann has nearly 30 years of experience in the pharmaceutical industry. After many years of service at Eli Lilly, in the scope of which he held several positions with marketing responsibility in Europe, Africa and South America and eventually managed the business in Germany, he joined Amgen in 2004. There, he was in charge of international operations before taking on his current position as Senior Vice President US Commercial Operations in 2012. With Mr. Hoffmann, STADA gains a proven expert in the pharmaceutical and biotechnological industries with extensive international experience and an in-depth understanding of how new markets can be accessed.
CV Rolf Hoffmann
- Dr. Birgit Kudlek (49), previously Chief Operating Officer at Aenova
Dr. Kudlek has more than 20 years of management experience in the chemical and pharmaceutical industries. After four years in a management position at the international management consulting firm Accenture she joined ratiopharm. There, she held various management positions, most recently she was responsible for global development activities. She was also active as Director of Technical Operations at LTS before taking on the role as Head of the Global Development Network at Sandoz. Dr. Kudlek, who holds a doctorate in pharmaceutical science and economics and is a proven expert in the generics industry, most recently extended her management experience as Chief Development and Production Officer at Aenova. She has been a Member of the Supervisory Board of the biotechnology company Wilex since 2012.
CV Dr. Birgit Kudlek
- Tina Müller (47), Chief Marketing Officer, at Opel
Ms. Müller is one of the best-known leadership personalities in the area of marketing and sales in Germany. In addition to her vast experience in the consumer goods/fast moving consumer goods area which she gained in her previous positions at Henkel, Wella and L’Oreal, she primarily brings international experience to the Company, as well as a perspective for the issue of digitalization, which is highly-relevant to STADA. Since 2013, Ms. Müller has been responsible for Marketing in her function as Member of the Executive Board at Opel. She has also been a member of various supervisory boards of the MLP Group since 2013.
CV Tina Müller
- Dr. Gunnar Riemann (58), previously Head of the Environmental Science global division at Bayer Crop Science
Dr. Riemann has more than 30 years of international experience in the lifescience industry. In recent years, Dr. Riemann, who is a registered pharmacist, was active in various Executive Board positions in the Healthcare and Crop Science divisions at Bayer in Germany, the USA and in France in areas such as consumer care, biological products, animal health and pharmaceuticals. Within the scope of his functions, he was in charge of various operational turnaround cases and accompanied the successful integration of Schering and Bayer Pharma.
CV Dr. Gunnar Riemann
The candidates will introduce themselves at the Annual General Meeting on August 26, 2016.
“With the proposed candidates, we have found four outstanding personalities who are highly suitable for the responsibilities of the Supervisory Board – not only because of their renowned international expertise in different industries and the capital markets, but also because of their qualifications on a personal level”, says Dr. Martin Abend, Chairman of the Supervisory Board of STADA Arzneimittel AG. “The Supervisory Board would like to thank the outgoing Member of the Supervisory Board Dieter Koch, who as Chairman of the Nomination Committee in an exemplary manner ensured a selection process that was in line with the expectations of our shareholders and met the highest corporate governance requirements. We are convinced that the presented candidates will make a substantial contribution to leading the Company to a sustainably successful future in cooperation with STADA’s operating management and to continuously increasing the value of the Company.
In May, the Supervisory Board had decided to start a structured process for a substantial personnel realignment of the committee two years earlier than planned in order to meet the requirements of the strategic development and internationalization of STADA. The Nomination Committee, which was formed for this purpose, selected the candidates with the help of Egon Zehnder using a clearly defined set of criteria. This was to ensure that the Supervisory Board in its entirety would unite relevant specialist and market knowledge in the generics and branded products area, pharmaceutical experience, expertise in financial, accounting and legal issues as well as personal independence following its new positioning. The Nomination Committee also took into account recommendations of the German Corporate Governance Code and international voting rights advisors. With its proposed candidates, the Nomination Committee also supports the increase of the proportion of women on the Supervisory Board of STADA Arzneimittel AG. If the Annual General Meeting accepts the proposal, the proportion of women both among the shareholder representatives and on the Supervisory Board as a whole would be one third.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: email@example.com
Or visit us in the Internet at www.stada.com.